Format

Send to

Choose Destination
Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26288. Epub 2016 Oct 17.

Precision medicine in pediatric oncology: Lessons learned and next steps.

Author information

1
Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan.
2
Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan.
3
Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts.
4
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
5
Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
6
Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
7
Department of Pathology and Michigan Center for Translational Pathology (MCTP), University of Michigan Medical School, Ann Arbor, Michigan.
8
Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, Michigan.

Abstract

The maturation of genomic technologies has enabled new discoveries in disease pathogenesis as well as new approaches to patient care. In pediatric oncology, patients may now receive individualized genomic analysis to identify molecular aberrations of relevance for diagnosis and/or treatment. In this context, several recent clinical studies have begun to explore the feasibility and utility of genomics-driven precision medicine. Here, we review the major developments in this field, discuss current limitations, and explore aspects of the clinical implementation of precision medicine, which lack consensus. Lastly, we discuss ongoing scientific efforts in this arena, which may yield future clinical applications.

KEYWORDS:

next-generation sequencing; oncology; precision medicine; targeted therapy

PMID:
27748023
PMCID:
PMC5683396
DOI:
10.1002/pbc.26288
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center